ntroduction of the Regional Program of Vaccination Against HPV-Associated Diseases in the Khanty-Mansi Autonomous Okrug (Yugra)

Prevalence of diseases associated with human papilloma virus (HPV) is high. The burden of this infection is so heavy all over the world, that the WHO recommended all countries to introduce vaccination against HPV into National Immunization Calendars. The article presents data on HPV prevalence in the Russian Federation in whole and the Khanty-Mansi Autonomous Okrug (Yugra) in particular, measures of timely identification of this disease and prevention of cervical cancer development. The program of school vaccination of female adolescent aged 12 years started operation in 2014 in Yugra. The author emphasizes the need in continuing with this program and introducing vaccination for male adolescents. According to the authors, introduction of preventive cohort vaccination against HPV into the regional and the National Calendars will reduce risk of development of oncological pathologies, such as cervical cancer and other HPV associated diseases, among the population.

1. Human Papillomavirus and Related Diseases Report World. Version posted on www.hpvcenter.net in March 17, 2014.

2. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006. Р. 489−498.

3. Munoz N., Castellsague X., de Gonzalez A.B., Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006; 24S3: S3/1–S3/10.

4. The WHO Position Paperon Vaccines against Human Papillomavirus. 2009. Available at: http://www.who.int/immunization/documents/HPV_position_paper_summary.pdf?ua=1

5. GLOBOCAN. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in World. Summary. Accessed on 09/09/2012. Available at: www.who.int/hpvcentre

6. Bychkova O.S., Kokolina V.F. Modern conceptions of human papillomavirus infection in children and adolescents. Reproduktivnoe zdorov'e detei i podrostkov – Reproductive health of children and adolescents. 2010; 1: 43−51.

7. Kumykova Z.Kh., Uvarova E.V. The prevalence and natural history of HPV infection and HPV-associated cervical lesions in adolescent girls. Reproduktivnoe zdorov'e detei i podrostkov – Reproductive health of children and adolescents. 2009; 5: 35−46.

8. Kaprin A.D., Starinskii V.V., Petrova V.G. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2012 g [State of Cancer Care in Russia in 2012]. Moscow, MNIOI im. Gertsena, 2013.

9. Chissov V.I. et al. Zlokachestvennye novoobrazovaniya v Rossii v 2011. Zabolevaemost' i smertnost' [Malignant Neoplasms in Russia in 2011. Morbidity and Mortality]. Moscow, 2013.

10. Gomberg M.A., Solov'ev A.M., Chernova N.I., Isaeva S.G. Genital warts: effective treatments. Meditsinskii vestnik – Medical bulletin. 2010; 5 (6): 10−12.

11. Galitskaya M.G., Namazova-Baranova L.S., Tkachenko N.E., Gaivoronskaya A.G. Vaccination against human papillomavirus infection: a safe solution to the global problem. Pediatricheskaya farmakologiya – Pediatric pharmacology. 2011; 8 (4).

12. Minkina G. N. Kvadrivalentnaya vaktsina Gardasil v profilaktike raka sheiki matki i genital'nykh kondilom. Materialy nauchno-praktich. konf. «Zdorov'e budushchikh pokolenii: novye tekhnologii i novye vozmozhnosti meditsiny» [Quadrivalent Vaccine Gardasil for Prevention of Cervical Cancer and Genital Warts. Proceedings of the scientific-practical Conference "Health of future generations, new technologies and new opportunities of medicine"]. Moscow, 2007. P. 12−17.

13. Tabrizi S.N., Brotherton J.M., Kaldor J.M., Skinner S.R., Cummins E., Liu B., Bateson D., McNamee K., Garefalakis M., Garland S.M. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012; 206 (11): 1645−1651.

14. Kontseptsiya i strategiya global'noi immunizatsii. Doklad sekretariata. VOZ 25 noyabrya 2010 goda (The concept and strategy of global immunization. Report of the Secretariat. WHO November 25, 2010). Available at: http://apps.who.int/gb/ebwha/pdf_files/EB128/B128_9-ru.pdf

15. Australia Therapeutic Goods Administration. Australia Government. Available at: http://agencysearch.australia.gov.au/s/search.html?query=gardasil&collection=agencies&profile=tga

16. Baandrup L., Blomberg M., Dehlendorff C., Sand C., Andersen K.K., Kjaer S.K. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013; 40: 130–135.

17. Brotherton J., Fridman M., May C., Chappell G., Saville M., Gertig D. Early effect of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011; 377 (2085): 92.

18. Canada Communicable Diseases Report: Update On Human Papillomavirus (HPV) Vaccines. An Advisory Committee Statement (ACS). NACI. 2012 Jan; 38. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/

19. Donovan B., Franklin N., Guy R., Grulich A., Regan D., Ali H., Wand H., Fairley Ch. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet. 2011; 11: 39–44.

20. Introduction of HPV vaccines in European Union countries-un update. 2012. Available at: http://www.ecdc.europa.eu/en/publications/publications/20120905_gui_hpv_vaccine_update

21. Markowitz L.E., Hariri S., Lin C., Dunne E.F., Steinau M., McQuillan G., Unger E.R. Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States. National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. Advance Access published. 2013, June 19.

22. Read T.R., Hocking J.S., Chen M.Y., Donovan B., Bradshaw C.S., Fairley C.K. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programmу. Sex Transm Infect. 2011.

23. Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males. Advisory Committee on Immunization Practices (ACIP). 2011. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm

24. Clinical Review of Biologics License Application for Human Papillomavirus 6, 11, 16, 18 L1 Virus Like Particle Vaccine. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm111287.pdf

25. FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010. Р. 340−349.

26. Stan L., Block M. et al. Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle Vaccine. Pediatr Infect Dis J. 2010; 29 (2).

27. Ali H., Guy R., Wand H., Read T., Regan D., Grulich A., Fairley Ch., Donovan B. Decline in In-Patient Treatments of Genital Warts Among Young Australians Following the National HPV Vaccination Program. BMC Infect Dis. 2013; 13: 140.

28. Bresse X., Cassel T., Adam M. Universal vaccination against 6/11/16/18 HPV-related diseases in Sweden: towards HPV disease control. EUROGIN 2013, European Research Organization on Genital Infection and Neoplasia 2013, International Multidisciplinary Congress. Florence, Italy. 2013. [Abstract P 3−3/].

29. Bresse X., Goergen C., Prager B., Joura E. Universal vaccination with the quadrivalent HPV vaccine in Austria: Impact on virus circulation, public health and cost-effectiveness analysis. Expert Rev. Pharmacoecon Outcomes Res. 2014, Early Online, Jan 22. 2014.

30. Harris T., Williams D.M., Fediurek J., Scott T., Deeks S.L. Adverse events following immunization in Ontario's female school-based HPV program. Vaccine. 2014; 32 (9): 1061.

31. Kothari S., Nwankwo C., Pillsbury M. The Health and Economic Impact of a Quadrivalent human papillomavirus vaccine (6/11/16/18) in Columbia: A Transmis. Dyn. Model-Based Evaluation. Value Health, A713. Abstr. PIN11. 2013, Nov 2; 16 (7).

32. Prymula R., Anca I., Andrе F., Bakir M. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines. Eur J Pediatr. 2009; 168 (9): 1031−1035.

33. Concept paper for a guideline on the conduct of pharmacovigilance for vaccines. European Medicines Agency. 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline

34. Dana A., Buchanan K.M., Goss M.A., Seminack M.M., Shields K.E., Korn S. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol. 2009; 114 (6): 1170−8. [CrossRef Medline].

35. Goss M.A., Lievano F., Seminack M., Buchanan K., Dana A. No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy: 5 year pregnancy registry data. Human Papillomavirus, Cervical Other Human Diseases. EUROGIN-2012. 2012, July 8−11. Р. 123. [Abstr. SS 8−3].

36. Klein N.P., Hansen J., Chao C., Velicer C., Emery M., Slezak J., Lewis N., Deosaransingh K., Sy L., Ackerson B., Cheetham T.C., Liaw K.-L., Takhar H., Jacobsen S.J. Safety of Quadrivalent Human Papillomavirus Vaccine Administered Routinely to Females. American Medical Association. 2012. URL: www.archpediatrics.com

37. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., Izurieta H.S., Ball R., Miller N., Braun M.M., Markowitz L.E., Iskander J. Post licensure safety surveillance for quadrivalenthuman papillomavirus recombinant vaccine. JAMA. 2009; 7: 750–757.

38. Garland S.M., Ault K.A., Gall S.A., Paavonen J., Sings H.L., Ciprero K.L., Saah A., Marino D., Ryan D., Radley D., Zhou H., Haupt R.M., Garner E.I. Pregnancy and Infant Outcomes in the Clinical Trials of a Human Papillomavirus Type 6/11/16/18 Vaccine. A Combined Analysis of Five Randomized Controlled Trials. Obst and Gynecol. 2009; 6: 1179−1188.